Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Peptic Ulcer

  Free Subscription


Articles published in Helicobacter

Retrieve available abstracts of 315 articles:
HTML format



Single Articles


    September 2024
  1. LE THI TG, Werkstetter K, Kotilea K, Bontems P, et al
    Factors Associated With Decision to Treat or Not to Treat Helicobacter pylori Infection in Children: Data From the EuroPedHp Registry.
    Helicobacter. 2024;29:e13134.
    PubMed     Abstract available


  2. CHEUNG KS, Lyu T, Deng Z, Han S, et al
    Vonoprazan Dual or Triple Therapy Versus Bismuth-Quadruple Therapy as First-Line Therapy for Helicobacter pylori Infection: A Three-Arm, Randomized Clinical Trial.
    Helicobacter. 2024;29:e13133.
    PubMed     Abstract available


  3. SUN L, Liu M, Gong Y, Zhai K, et al
    Rapid Antimicrobial Susceptibility Test of Helicobacter pylori to Metronidazole via Single-Cell Raman Spectrometry.
    Helicobacter. 2024;29:e13136.
    PubMed     Abstract available



  4. Correction to "Long-Term Effects of Fecal Microbiota Transplantation on Gut Microbiota After Helicobacter pylori Eradication With Bismuth Quadruple Therapy: A Randomized Controlled Trial".
    Helicobacter. 2024;29:e13127.
    PubMed    


  5. LIU N, Luo Q, Gou L, Shen X, et al
    Knowledge and Practices of Helicobacter pylori Infection Management Among Physicians in Gansu Province, China: A Cross-Sectional Study.
    Helicobacter. 2024;29:e13137.
    PubMed     Abstract available


  6. HUANG Y, Qiu S, Guo Y, Chen J, et al
    Optimization of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Real-World Evidence Study.
    Helicobacter. 2024;29:e13138.
    PubMed     Abstract available


    July 2024
  7. LI B, He J, Zhang R, Liu S, et al
    Integrin-Linked Kinase in the Development of Gastric Tumors Induced by Helicobacter pylori: Regulation and Prevention Potential.
    Helicobacter. 2024;29:e13109.
    PubMed     Abstract available


  8. LI XT, Xu L, Zhang C, Qi YB, et al
    Improved Patient Adherence to Family-Based Helicobacter pylori Infection Control and Management Strategy in Central China and Its Influencing Factors.
    Helicobacter. 2024;29:e13114.
    PubMed     Abstract available


  9. JAUVAIN M, Lepied G, Benejat L, Roudier N, et al
    Effect of Lactobacillus gasseri BIO6369 and Lacticaseibacillus rhamnosus BIO5326 on Gastric Carcinogenesis Induced by Helicobacter pylori Infection.
    Helicobacter. 2024;29:e13108.
    PubMed     Abstract available


  10. MARTINEZ-DOMINGUEZ SJ, Nyssen OP, Lanas A, Alfaro E, et al
    Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg).
    Helicobacter. 2024;29:e13111.
    PubMed     Abstract available


  11. CABRERA C, Torres J, Serrano CA, Gallardo P, et al
    Antimicrobial Resistance of Helicobacter pylori Isolated From Latin American Children and Adolescents (2008-2023): A Systematic Review.
    Helicobacter. 2024;29:e13101.
    PubMed     Abstract available


  12. ZHAO JT, Zhang Y, Wang XW, Zou PY, et al
    Long-term effects of fecal microbiota transplantation on gut microbiota after Helicobacter pylori eradication with bismuth quadruple therapy: A randomized controlled trial.
    Helicobacter. 2024;29:e13079.
    PubMed     Abstract available


  13. QIU S, Huang Y, Chen J, Guo Y, et al
    Vonoprazan-Amoxicillin Dual Therapy With Different Amoxicillin Administration Regimens for Helicobacter pylori Treatment: A Randomized Controlled Trial.
    Helicobacter. 2024;29:e13118.
    PubMed     Abstract available


  14. DORE MP, Hernaez R, Graham DY
    Self-Correcting Method for Highly Effective Office-Based Helicobacter pylori Therapy Using Cumulative Test of Cure Data.
    Helicobacter. 2024;29:e13112.
    PubMed     Abstract available


  15. HU Y, Lai Y, Liao F, Shu X, et al
    Assessing Accuracy of ChatGPT on Addressing Helicobacter pylori Infection-Related Questions: A National Survey and Comparative Study.
    Helicobacter. 2024;29:e13116.
    PubMed     Abstract available


  16. MELNIK P, Weintraub I, Shamaly H, Cohen S, et al
    Helicobacter pylori-Associated Extranodal Marginal Zone Lymphoma of Mucosa-Associated Tissue in Children: A Multicenter Case Series.
    Helicobacter. 2024;29:e13113.
    PubMed     Abstract available


  17. MA Y, Zhou X, Liu Y, Xu S, et al
    An Economic Evaluation of Family-Based Versus Traditional Helicobacter pylori Screen-and-Treat Strategy: Based on Real-World Data and Microsimulation Model.
    Helicobacter. 2024;29:e13123.
    PubMed     Abstract available



  18. Correction to Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg).
    Helicobacter. 2024;29:e13124.
    PubMed    


  19. LIU Z, Li H, Huang X, Liu Q, et al
    Animal Models of Helicobacter pylori Infection and Vaccines: Current Status and Future Prospects.
    Helicobacter. 2024;29:e13119.
    PubMed     Abstract available


  20. ZHOU S, Zheng Z, Wang L, Song W, et al
    Correlation of FUT3 and FUT6 Gene Polymorphisms With Helicobacter pylori Infection.
    Helicobacter. 2024;29:e13122.
    PubMed     Abstract available


  21. ZENG S, Kong Q, Wu X, Ma T, et al
    Artificial Intelligence-Generated Patient Education Materials for Helicobacter pylori Infection: A Comparative Analysis.
    Helicobacter. 2024;29:e13115.
    PubMed     Abstract available


  22. DING YM, Zhang QM, Li RL, Han ZX, et al
    Tetracycline Three Times Daily Versus Four Times Daily in Bismuth-Containing Quadruple Therapy as the First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial.
    Helicobacter. 2024;29:e13121.
    PubMed     Abstract available


  23. YANG P, Jiang J
    Letter to the Editor Regarding the Article: "Exploring the Capacities of ChatGPT: A Comprehensive Evaluation of Its Accuracy and Repeatability in Addressing Helicobacter pylori-Related Queries".
    Helicobacter. 2024;29:e13131.
    PubMed    


  24. KIM JS, Kim BW, Kim JI, Chung WC, et al
    Empirical Therapy Versus Tailored Therapy of Helicobacter pylori in Korea: Results of the K-CREATE Study.
    Helicobacter. 2024;29:e13126.
    PubMed     Abstract available


  25. KOWADA A
    Cost-Effectiveness of Population-Based Helicobacter pylori Screening With Eradication for Optimal Age of Implementation.
    Helicobacter. 2024;29:e13120.
    PubMed     Abstract available


  26. ZHANG Z, Cui M, Ji X, Su G, et al
    Candidate Antigens and the Development of Helicobacter pylori Vaccines.
    Helicobacter. 2024;29:e13128.
    PubMed     Abstract available


  27. CHIU YT, Lee FJ, Kuo CY, Chen YT, et al
    Seven-Day Vonoprazan-Based Triple Therapy as First-Line Helicobacter pylori Treatment in Comparison With Extended Sequential Therapy: A Randomized Controlled Trial.
    Helicobacter. 2024;29:e13129.
    PubMed     Abstract available


  28. XIA C, Chen Z, Chen Y, Wei F, et al
    Effects of Latilactobacillus sakei LZ217 on Gastric Mucosal Colonization, Metabolic Interference, and Urease Expression in Helicobacter pylori Infection.
    Helicobacter. 2024;29:e13130.
    PubMed     Abstract available


  29. IWATA E, Sugimoto M, Asaoka D, Hojo M, et al
    Characteristics of Helicobacter pylori Eradication Therapy in Patients 80 Years or Older Living in a Metropolitan Area: A Multicenter Retrospective Study.
    Helicobacter. 2024;29:e13125.
    PubMed     Abstract available


    May 2024
  30. JUNG K, Jee SR, Lee MW, Koh M, et al
    Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non-inferiority study.
    Helicobacter. 2024;29:e13084.
    PubMed     Abstract available


  31. KAOUAH Z, Buyck JM, Pichon M, Burucoa C, et al
    In vitro efficacy of combinations of antibiotics used in clinical practice on clinical isolates of Helicobacter pylori.
    Helicobacter. 2024;29:e13081.
    PubMed     Abstract available


  32. ARFI S, Sharma P, Kumar M, Mehra S, et al
    Antibiotic susceptibility pattern of Helicobacter pylori against eight antibiotics: A study from North India.
    Helicobacter. 2024;29:e13093.
    PubMed     Abstract available


  33. XIE J, Peng J, Liu D, Zeng R, et al
    Treatment failure is a key factor in the development of Helicobacter pylori resistance.
    Helicobacter. 2024;29:e13091.
    PubMed     Abstract available


  34. TALAYEV V, Svetlova M, Zaichenko I, Voronina E, et al
    CCR6(+) T helper cells and regulatory T cells in the blood and gastric mucosa during Helicobacter pylori infection.
    Helicobacter. 2024;29:e13097.
    PubMed     Abstract available


  35. KAYAMBA V, Munshi H, Hankolwe MN, Kaluba Kavimba C, et al
    Nationwide survey of Helicobacter pylori seropositivity and gastric atrophy in Zambia.
    Helicobacter. 2024;29:e13096.
    PubMed     Abstract available


  36. KOTILEA K, Romano C, Miele E, Kindermann A, et al
    Helicobacter pylori infection found during upper endoscopy performed for the diagnosis of celiac, inflammatory bowel diseases, and eosinophilic esophagitis: A multicenter pediatric European study.
    Helicobacter. 2024;29:e13092.
    PubMed     Abstract available


  37. ZHANG C, Qi YB, Hu RB, Xu L, et al
    Family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are highly cost-effective in preventing multiple upper gastrointestinal diseases in Chinese population at national level.
    Helicobacter. 2024;29:e13063.
    PubMed     Abstract available


  38. HAN Z, Zhang Q, Mirza IA, Ding Y, et al
    Efficacy of Tetracycline Three Times Daily was Comparable to That of Four Times Daily for Helicobacter pylori Rescue Treatment: A Multicenter, Noninferiority, Randomized Controlled Trial.
    Helicobacter. 2024;29:e13102.
    PubMed     Abstract available


  39. YU J, He Y, Yao W, Liu T, et al
    Helicobacter pylori CagA Promotes the Formation of Gallstones by Increasing the Permeability of Gallbladder Epithelial Cells.
    Helicobacter. 2024;29:e13100.
    PubMed     Abstract available


  40. LAI Y, Liao F, Zhao J, Zhu C, et al
    Exploring the capacities of ChatGPT: A comprehensive evaluation of its accuracy and repeatability in addressing helicobacter pylori-related queries.
    Helicobacter. 2024;29:e13078.
    PubMed     Abstract available


  41. KONG Q, Mirza IA, Zhang X, Song X, et al
    Fourteen-Day Tegoprazan-Amoxicillin Dual Therapy as the First-Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial.
    Helicobacter. 2024;29:e13098.
    PubMed     Abstract available


  42. YU Y, Xue J, Lin F, Liu D, et al
    Global Primary Antibiotic Resistance Rate of Helicobacter pylori in Recent 10 years: A Systematic Review and Meta-Analysis.
    Helicobacter. 2024;29:e13103.
    PubMed     Abstract available


  43. JAFARZADEH A, Jafarzadeh Z, Nemati M, Yoshimura A, et al
    The Interplay Between Helicobacter pylori and Suppressors of Cytokine Signaling (SOCS) Molecules in the Development of Gastric Cancer and Induction of Immune Response.
    Helicobacter. 2024;29:e13105.
    PubMed     Abstract available


  44. MOGES ESKEZIYAW B, Waihenya R, Maina N, Muuo Nzou S, et al
    Immunoinformatics-Based Designing of Novel and Potent Multi-Epitope PSA D15 and Cag11 Immunogens for Helicobacter pylori Immunodiagnostic Assay Development.
    Helicobacter. 2024;29:e13104.
    PubMed     Abstract available


  45. DORE MP, Meloni G, Bassu I, Pes GM, et al
    Helicobacter pylori Infection Does Not Protect Against Allergic Diseases: Evidence From a Pediatric Cohort From Northern Sardinia, Italy.
    Helicobacter. 2024;29:e13107.
    PubMed     Abstract available


  46. SAHARA S, Sugimoto M, Murata M, Iwata E, et al
    Eradication Therapy for Helicobacter pylori Infection in Patients Receiving Hemodialysis: Review.
    Helicobacter. 2024;29:e13106.
    PubMed     Abstract available


    March 2024
  47. YANG H, Zhang M, Ma G, Yang J, et al
    Meta-analysis of Helicobacter pylori eradication therapy using vonoprazan as an acid suppressor compared with bismuth quadruple therapy.
    Helicobacter. 2024;29:e13059.
    PubMed     Abstract available


  48. CHEN S, Zhao H, Tian Y, Wu Q, et al
    Antagonizing roles of SHP1 in the pathogenesis of Helicobacter pylori infection.
    Helicobacter. 2024;29:e13066.
    PubMed     Abstract available


  49. VANGRAVS R, Mezmale L, Slefarska-Wolak D, Dauss E, et al
    Volatilomic signatures of different strains of Helicobacter pylori.
    Helicobacter. 2024;29:e13064.
    PubMed     Abstract available


  50. TSUDA M, Watanabe Y, Oikawa R, Watanabe R, et al
    Impact of mixed-infection rate of clarithromycin-susceptible and clarithromycin-resistant Helicobacter pylori strains on the success rate of clarithromycin-based eradication treatment.
    Helicobacter. 2024;29:e13062.
    PubMed     Abstract available


  51. APOORVA E, Jacob R, Rao DN, Kumar S, et al
    Helicobacter pylori enhances HLA-C expression in the human gastric adenocarcinoma cells AGS and can protect them from the cytotoxicity of natural killer cells.
    Helicobacter. 2024;29:e13069.
    PubMed     Abstract available


  52. PEYPAR MH, Yeganeh AV, Ramazani A, Alizadeh A, et al
    Oral immunotherapy for Helicobacter pylori: Can it be trusted? A systematic review.
    Helicobacter. 2024;29:e13067.
    PubMed     Abstract available


  53. OKAMURA T, Iwaya Y, Nagaya T, Horiuchi K, et al
    Diagnosis by combination of endoscopic findings helps differentiate non-Helicobacter pylori Helicobacter-infected gastritis from Helicobacter pylori-infected gastritis.
    Helicobacter. 2024;29:e13070.
    PubMed     Abstract available


  54. LUO Q, Liu C, Zhang A, Zhang D, et al
    Research progress in photodynamic therapy for Helicobacter pylori infection.
    Helicobacter. 2024;29:e13068.
    PubMed     Abstract available


  55. MI C, Suo B, Tian X, Wang Y, et al
    Application of cefuroxime in the eradication therapy of Helicobacter pylori infection: A review article.
    Helicobacter. 2024;29:e13073.
    PubMed     Abstract available


  56. LARA ICAZA JD, Tapia RL, Triana CTC, Ramirez LCR, et al
    Refractoriness to anti-Helicobacter pylori treatment attributed to phenotypic resistance patterns in patients with gastroduodenopathy in Guayaquil-Ecuador.
    Helicobacter. 2024;29:e13060.
    PubMed     Abstract available


  57. LIU J, Jia J, Shi T, Bai Y, et al
    Evaluating the potency of zoliflodacin against Helicobacter pylori: In vitro activity and conserved GyrB target.
    Helicobacter. 2024;29:e13075.
    PubMed     Abstract available


  58. MOFIDIFAR S, Yadegar A, Karimi-Jafari MH
    A reconstructed genome-scale metabolic model of Helicobacter pylori for predicting putative drug targets in clarithromycin and rifampicin resistance conditions.
    Helicobacter. 2024;29:e13074.
    PubMed     Abstract available


  59. GUAN X, Ning J, Fu W, Wang Y, et al
    Helicobacter pylori with trx1 high expression promotes gastric diseases via upregulating the IL23A/NF-kappaB/IL8 pathway.
    Helicobacter. 2024;29:e13072.
    PubMed     Abstract available


  60. CHEN J, Zhang Y, Min H, Zhi J, et al
    Dynamic changes in the gut microbiota after bismuth quadruple therapy and high-dose dual therapy for Helicobacter pylori eradication.
    Helicobacter. 2024;29:e13077.
    PubMed     Abstract available


  61. AMIOT A, Hacoon J, Heluwaert F, Mion F, et al
    14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial.
    Helicobacter. 2024;29:e13076.
    PubMed     Abstract available


  62. STERBENC A, Godnov U, Vodicar PM, Simcic S, et al
    Prevalence of Helicobacter pylori infection among Slovenian children and adolescents: A prospective cohort study.
    Helicobacter. 2024;29:e13082.
    PubMed     Abstract available


  63. KATO M, Ono S, Kawada K, Dohi O, et al
    Diagnostic performance of linked color imaging for gastric cancer by Helicobacter pylori infection status: A subanalysis of the large-scale, multicenter randomized controlled trial LCI-FIND.
    Helicobacter. 2024;29:e13080.
    PubMed     Abstract available


  64. AGAWA H, Tsukadaira T, Kobayashi N, Kodaira H, et al
    Four cases of non-Helicobacter pylori Helicobacter-infected gastritis with duodenal spiral bacilli.
    Helicobacter. 2024;29:e13083.
    PubMed     Abstract available


    January 2024
  65. VON MUHLENBROCK C, Cordova A, Nunez P, Pacheco N, et al
    Eradication rate and adherence with high-dose amoxicillin and proton pump inhibitor as first-line treatment for Helicobacter pylori infection: Experience from University Hospital in Chile.
    Helicobacter. 2024;29:e13052.
    PubMed     Abstract available


  66. MARZHOSEYNI Z, Mousavi MJ, Ghotloo S
    Helicobacter pylori antigens as immunomodulators of immune system.
    Helicobacter. 2024;29:e13058.
    PubMed     Abstract available


  67. DUTTA S, Jain S, Das K, Verma P, et al
    Primary antibiotic resistance of Helicobacter pylori in India over the past two decades: A systematic review.
    Helicobacter. 2024;29:e13057.
    PubMed     Abstract available


  68. TIRGAR FAKHERI S, Shokri-Afra H, Graham DY, Bari Z, et al
    A pilot study evaluating high dose esomeprazole, bismuth subcitrate and amoxicillin for eradicating Helicobacter pylori infection in Iran.
    Helicobacter. 2024;29:e13061.
    PubMed     Abstract available


  69. LO HY, Yang YJ
    Seroprevalence of Helicobacter pylori infection among schoolchildren in southern Taiwan-A 20-year longitudinal follow-up.
    Helicobacter. 2024;29:e13049.
    PubMed     Abstract available


  70. WU X, Duan M, Kong Q, Zeng S, et al
    Clarifying varied Helicobacter pylori eradication therapies: A comprehensive review.
    Helicobacter. 2024;29:e13048.
    PubMed     Abstract available


  71. JU KP, Kong QZ, Li YY, Li YQ, et al
    Low-dose or high-dose amoxicillin in vonoprazan-based dual therapy for Helicobacter pylori eradication? A systematic review and meta-analysis.
    Helicobacter. 2024;29:e13054.
    PubMed     Abstract available


  72. MATSUMOTO S, Sugimoto M, Fukuzawa M, Uesugi N, et al
    Risk of map-like redness development after eradication therapy for Helicobacter pylori infection.
    Helicobacter. 2024;29:e13046.
    PubMed     Abstract available


  73. KONG QZ, Ju KP, Wan M, Liu J, et al
    Comparative analysis of large language models in medical counseling: A focus on Helicobacter pylori infection.
    Helicobacter. 2024;29:e13055.
    PubMed     Abstract available


  74. HU Y, Huang XH, Zhou B, Liu ML, et al
    Vonoprazan and amoxicillin dual therapy for 14 days as the first-line treatment of Helicobacter pylori infection: A non-inferiority, randomized clinical trial.
    Helicobacter. 2024;29:e13045.
    PubMed     Abstract available


    November 2023
  75. DU RC, Hu YX, Ouyang Y, Ling LX, et al
    Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis.
    Helicobacter. 2023 Nov 30:e13039. doi: 10.1111/hel.13039.
    PubMed     Abstract available


  76. LIANG Y, Yang Y, Nong R, Huang H, et al
    Do atrophic gastritis and intestinal metaplasia reverse after Helicobacter pylori eradication?
    Helicobacter. 2023 Nov 29:e13042. doi: 10.1111/hel.13042.
    PubMed     Abstract available


  77. FENG Y, Huang Q, Luo M, Wei J, et al
    The association between Helicobacter pylori and gastrointestinal disorders during pregnancy: A Multicenter retrospective study.
    Helicobacter. 2023 Nov 27:e13032. doi: 10.1111/hel.13032.
    PubMed     Abstract available


  78. MELO J, Cavadas B, Pereira L, Figueiredo C, et al
    Transcriptomic remodeling of gastric cells by Helicobacter pylori outer membrane vesicles.
    Helicobacter. 2023 Nov 23:e13031. doi: 10.1111/hel.13031.
    PubMed     Abstract available


  79. LIM NR, Kim J, Chung WC
    Recurrence of Helicobacter pylori following successful eradication and clinical outcomes in Korean patients.
    Helicobacter. 2023 Nov 20:e13036. doi: 10.1111/hel.13036.
    PubMed     Abstract available


  80. XU W, Yang B, Lin L, Lin Q, et al
    Antibiotic resistance of Helicobacter pylori in Chinese children: A multicenter study from 2016 to 2023.
    Helicobacter. 2023 Nov 20:e13038. doi: 10.1111/hel.13038.
    PubMed     Abstract available


  81. ZHOU BG, Jiang X, Ding YB, She Q, et al
    Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
    Helicobacter. 2023 Nov 20:e13040. doi: 10.1111/hel.13040.
    PubMed     Abstract available


  82. VERNON-ROBERTS A, Premaratne M, Wright R, Keenan JI, et al
    Profile of Helicobacter pylori infections among children in the South Island of New Zealand (2010-2021).
    Helicobacter. 2023 Nov 20:e13037. doi: 10.1111/hel.13037.
    PubMed     Abstract available


  83. YUNLE K, Tong W, Jiyang L, Guojun W, et al
    Advances in Helicobacter pylori vaccine research: From candidate antigens to adjuvants-A review.
    Helicobacter. 2023 Nov 16:e13034. doi: 10.1111/hel.13034.
    PubMed     Abstract available


  84. FANI T, Ioannis TG
    Letter to the Editor regarding the article: "Forty years of Helicobacter pylori infection and changes in findings at esophagogastroduodenoscopy".
    Helicobacter. 2023 Nov 13:e13035. doi: 10.1111/hel.13035.
    PubMed    


  85. LEE CT, Wu CT, Chang WL, Yang EH, et al
    The nonadherence and risk factors of eradication failure by sequential therapy as first-line anti-Helicobacter pylori treatment in real-world clinical practice.
    Helicobacter. 2023 Nov 10:e13033. doi: 10.1111/hel.13033.
    PubMed     Abstract available


    October 2023
  86. YE J, Feng T, Su L, Li J, et al
    Interactions between Helicobacter pylori infection and host metabolic homeostasis: A comprehensive review.
    Helicobacter. 2023 Oct 23:e13030. doi: 10.1111/hel.13030.
    PubMed     Abstract available


  87. YOUSEFI M, Rezaei S, Khoshbaten M, Sarmasti M, et al
    Cost-effectiveness analysis of different screening strategies for helicobacter pylori infection in Iran: A model-based evaluation.
    Helicobacter. 2023 Oct 15:e13027. doi: 10.1111/hel.13027.
    PubMed     Abstract available


  88. GAO W, Zhu M, Yin Y, Zhang X, et al
    Efficacy and safety of minocycline quadruple therapy for Helicobacter pylori eradication: A meta-analysis of RCTs.
    Helicobacter. 2023 Oct 15:e13022. doi: 10.1111/hel.13022.
    PubMed     Abstract available


  89. TAN W, Liu Y, Shi Z, Zheng B, et al
    Information quality of videos related to Helicobacter pylori infection on TikTok: Cross-sectional study.
    Helicobacter. 2023 Oct 12:e13029. doi: 10.1111/hel.13029.
    PubMed     Abstract available


  90. OKIMOTO T, Ando T, Sasaki M, Ono S, et al
    Antimicrobial-resistant Helicobacter pylori in Japan: Report of nationwide surveillance for 2018-2020.
    Helicobacter. 2023 Oct 12:e13028. doi: 10.1111/hel.13028.
    PubMed     Abstract available


  91. O'CONNOR HJ
    Forty years of Helicobacter pylori infection and changes in findings at esophagogastroduodenoscopy.
    Helicobacter. 2023 Oct 11:e13026. doi: 10.1111/hel.13026.
    PubMed     Abstract available


  92. WU S, Chen Y, Chen Z, Wei F, et al
    Reactive oxygen species and gastric carcinogenesis: The complex interaction between Helicobacter pylori and host.
    Helicobacter. 2023 Oct 5:e13024. doi: 10.1111/hel.13024.
    PubMed     Abstract available


  93. DORE MP, Erre GL, Piroddu J, Pes GM, et al
    Helicobacter pylori infection and rheumatoid arthritis as risk enhancers' factors for atherosclerotic cardiovascular diseases.
    Helicobacter. 2023 Oct 4:e13025. doi: 10.1111/hel.13025.
    PubMed     Abstract available


    September 2023
  94. VESGA FJ, Beltran-Benavides AR, Marquez-Duque AM, Venegas C, et al
    Helicobacter pylori virulence genotypes in Bogota River and wastewater treatment plants in Colombia.
    Helicobacter. 2023 Sep 27:e13023. doi: 10.1111/hel.13023.
    PubMed     Abstract available


  95. RATANA-AMORNPIN S, Sanglutong L, Eiamsitrakoon T, Siramolpiwat S, et al
    Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan.
    Helicobacter. 2023 Sep 18:e13019. doi: 10.1111/hel.13019.
    PubMed     Abstract available


  96. LI Y, Ouyang Y, He C
    Research trends on the relationship between Helicobacter pylori and microbiota: A bibliometric analysis.
    Helicobacter. 2023 Sep 11:e13021. doi: 10.1111/hel.13021.
    PubMed     Abstract available


  97. ZHANG X, Zhang K, Yan L, Wang P, et al
    The role of toll-like receptors in immune tolerance induced by Helicobacter pylori infection.
    Helicobacter. 2023 Sep 10:e13020. doi: 10.1111/hel.13020.
    PubMed     Abstract available


  98. GONG X, Shen L, Xie J, Liu D, et al
    Helicobacter pylori infection reduces the efficacy of cancer immunotherapy: A systematic review and meta-analysis.
    Helicobacter. 2023 Sep 3:e13011. doi: 10.1111/hel.13011.
    PubMed     Abstract available


    August 2023
  99. LIN K, Huang L, Wang Y, Li K, et al
    Efficacy of genotypic susceptibility-guided tailored therapy for Helicobacter pylori infection: A systematic review and single arm meta-analysis.
    Helicobacter. 2023 Aug 27:e13015. doi: 10.1111/hel.13015.
    PubMed     Abstract available


  100. QUACH DT, Vilaichone RK, Luu MN, Lee YY, et al
    Real-world practice of Helicobacter pylori management: A survey among physicians in Southeast Asia.
    Helicobacter. 2023 Aug 27:e13018. doi: 10.1111/hel.13018.
    PubMed     Abstract available


  101. YU Z, Zhang X, Zhao Q, Yan X, et al
    Urolithin B alleviates Helicobacter pylori-induced inflammation and oxidative stress in mice.
    Helicobacter. 2023 Aug 25:e13016. doi: 10.1111/hel.13016.
    PubMed     Abstract available


  102. ISMAIL NI, Nawawi KNM, Hsin DCC, Hao KW, et al
    Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double-blind, placebo-controlled trial.
    Helicobacter. 2023 Aug 23:e13017. doi: 10.1111/hel.13017.
    PubMed     Abstract available


  103. ZHU F, Zhang X, Li P, Zhu Y, et al
    Effect of Helicobacter pylori eradication on gastric precancerous lesions: A systematic review and meta-analysis.
    Helicobacter. 2023 Aug 21:e13013. doi: 10.1111/hel.13013.
    PubMed     Abstract available


  104. SU NY, Shi Q, Mei H, Hu J, et al
    Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis.
    Helicobacter. 2023 Aug 10:e13003. doi: 10.1111/hel.13003.
    PubMed     Abstract available


  105. BAWAND R, Ghiasian M, Samadyan M, Qaderi S, et al
    Association of Helicobacter pylori with migraine headaches and the effects of this infection and its eradication on the migraine characteristics in adults: A comprehensive systematic review and meta-analysis.
    Helicobacter. 2023 Aug 2:e13010. doi: 10.1111/hel.13010.
    PubMed     Abstract available


    July 2023
  106. DU RC, Ouyang YB, Lu NH, Hu Y, et al
    Research trends on vonoprazan-based therapy for Helicobacter pylori eradication: A bibliometric analysis from 2015 to 2023.
    Helicobacter. 2023 Jul 29:e13012. doi: 10.1111/hel.13012.
    PubMed     Abstract available


  107. NGUYEN TC, Le GKN, Pham DTH, Pham BV, et al
    Antibiotic resistance and heteroresistance in Helicobacter pylori isolates from symptomatic Vietnamese children: A prospective multicenter study.
    Helicobacter. 2023 Jul 27:e13009. doi: 10.1111/hel.13009.
    PubMed     Abstract available


  108. LIMA IS, da Silva TM, Weiss S, Homuth G, et al
    Genome-wide association study of Helicobacter pylori serological status in Latin American children.
    Helicobacter. 2023 Jul 27:e13008. doi: 10.1111/hel.13008.
    PubMed     Abstract available


  109. DU RC, Zhang Y, Wang MH, Lu NH, et al
    TikTok and Bilibili as sources of information on Helicobacter pylori in China: A content and quality analysis.
    Helicobacter. 2023 Jul 15:e13007. doi: 10.1111/hel.13007.
    PubMed     Abstract available


  110. KOTILEA K, Iliadis E, Nguyen J, Salame A, et al
    Antibiotic resistance, heteroresistance, and eradication success of Helicobacter pylori infection in children.
    Helicobacter. 2023 Jul 4:e13006. doi: 10.1111/hel.13006.
    PubMed     Abstract available


    June 2023
  111. HASSAN SS, Nader M, Nagy M, Mohamed M, et al
    Antimicrobial screening involving Helicobacter pylori of nano-therapeutic compounds based on the amoxicillin antibiotic drug.
    Helicobacter. 2023 Jun 30:e13004. doi: 10.1111/hel.13004.
    PubMed     Abstract available


  112. ZHANG Y, Zhao Z, Fu W, Ding S, et al
    The expression and function of the B7 family in Helicobacter pylori infection and gastric carcinogenesis process.
    Helicobacter. 2023 Jun 29:e12999. doi: 10.1111/hel.12999.
    PubMed     Abstract available


  113. ZHANG Z, Chen X, Li B, Xia T, et al
    Helicobacter pylori induces urease subunit B-specific CD8(+) T cell responses in infected individuals via cytosolic pathway of cross-presentation.
    Helicobacter. 2023 Jun 29:e13005. doi: 10.1111/hel.13005.
    PubMed     Abstract available


  114. BARREYRO FJ, Maiorana F, Caronia MV, Elizondo K, et al
    Association between genetic polymorphisms of NOD1, Interleukin-1B, and cagA strain with low-grade duodenal eosinophilia in Helicobacter pylori-related dyspepsia.
    Helicobacter. 2023 Jun 23:e13002. doi: 10.1111/hel.13002.
    PubMed     Abstract available


  115. ISMAIL M, Majaliwa ND, Vale FF, Cumbana R, et al
    Molecular detection of Helicobacter pylori and its genotypic antimicrobial resistance patterns in dyspeptic Mozambican patients.
    Helicobacter. 2023 Jun 20:e13000. doi: 10.1111/hel.13000.
    PubMed     Abstract available


  116. KATSANDE PM, Nguyen VD, Nguyen TLP, Nguyen TKC, et al
    Prophylactic immunization to Helicobacter pylori infection using spore vectored vaccines.
    Helicobacter. 2023 Jun 14:e12997. doi: 10.1111/hel.12997.
    PubMed     Abstract available


  117. LEE SY, Kim JH, Sung IK, Park HS, et al
    Twice-daily intake of bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: A retrospective study on 10-day, 14-day, and half-dose antibiotic therapy.
    Helicobacter. 2023 Jun 9:e12998. doi: 10.1111/hel.12998.
    PubMed     Abstract available


    May 2023
  118. JIANG F, Ju C, Guo CG, Cheung KS, et al
    Risk of hospitalization for upper gastrointestinal bleeding in Helicobacter pylori eradicated patients newly started on warfarin or direct oral anticoagulants: A population-based cohort study.
    Helicobacter. 2023 May 29:e12990. doi: 10.1111/hel.12990.
    PubMed     Abstract available


  119. ZENG R, Li X, Wang F, Xie J, et al
    Reinforced medication adherence improves Helicobacter pylori eradication rate in developing countries: A systematic review and meta-analysis of randomized controlled trials.
    Helicobacter. 2023 May 17:e12989. doi: 10.1111/hel.12989.
    PubMed     Abstract available


  120. HU J, Mei H, Su NY, Sun WJ, et al
    Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China.
    Helicobacter. 2023 May 9:e12970. doi: 10.1111/hel.12970.
    PubMed     Abstract available


  121. KARAYIANNIS I, Martinez-Gonzalez B, Kontizas E, Kokkota AV, et al
    Induction of MMP-3 and MMP-9 expression during Helicobacter pylori infection via MAPK signaling pathways.
    Helicobacter. 2023 May 4:e12987. doi: 10.1111/hel.12987.
    PubMed     Abstract available


  122. WANG R, Huang S, Gan P, Pan X, et al
    States and hotspots in Helicobacter pylori research from 2002 to 2021: A bibliometric analysis.
    Helicobacter. 2023 May 3:e12986. doi: 10.1111/hel.12986.
    PubMed     Abstract available


    April 2023
  123. MCNULTY CAM
    The first 5 years of Helicobacter pylori research-With an emphasis on the United Kingdom.
    Helicobacter. 2023 Apr 27:e12982. doi: 10.1111/hel.12982.
    PubMed     Abstract available


  124. LI M, Gao N, Wang S, Guo Y, et al
    Bibliometric analysis of Helicobacter pylori resistance-from 2002 to 2022.
    Helicobacter. 2023 Apr 27:e12983. doi: 10.1111/hel.12983.
    PubMed     Abstract available


  125. ZANG H, Wang J, Wang H, Guo J, et al
    Metabolic alterations in patients with Helicobacter pylori-related gastritis: The H. pylori-gut microbiota-metabolism axis in progression of the chronic inflammation in the gastric mucosa.
    Helicobacter. 2023 Apr 25:e12984. doi: 10.1111/hel.12984.
    PubMed     Abstract available


  126. KIM JS, Ko W, Chung JW, Kim TH, et al
    Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study.
    Helicobacter. 2023 Apr 21:e12977. doi: 10.1111/hel.12977.
    PubMed     Abstract available


  127. HAN X, Yu X, Gao X, Wang X, et al
    Quantitative PCR of string-test collected gastric material: A feasible approach to detect Helicobacter pylori and its resistance against clarithromycin and levofloxacin for susceptibility-guided therapy.
    Helicobacter. 2023 Apr 17:e12985. doi: 10.1111/hel.12985.
    PubMed     Abstract available


  128. HU S, Zhou Y, Deng Y, Bo Y, et al
    Characteristics of phenotypic antibiotic resistance of Helicobacter pylori and its correlation with genotypic antibiotic resistance: A retrospective study in Ningxia.
    Helicobacter. 2023 Apr 11:e12960. doi: 10.1111/hel.12960.
    PubMed     Abstract available


  129. SOH H, Kim N, Moon J, Lee HM, et al
    Gastric mucosal swab as an alternative to biopsy for Helicobacter pylori detection.
    Helicobacter. 2023 Apr 7:e12980. doi: 10.1111/hel.12980.
    PubMed     Abstract available


  130. YU H, Li J, Liu X, Chen Z, et al
    Helicobacter pylori bacteremia presenting as seizure and unconsciousness: The brief case.
    Helicobacter. 2023 Apr 5:e12973. doi: 10.1111/hel.12973.
    PubMed     Abstract available


  131. ZENG R, Xie Y
    Inquiry about methodology used to isolate multiple Helicobacter pylori strains from the same patient.
    Helicobacter. 2023 Apr 3:e12981. doi: 10.1111/hel.12981.
    PubMed    


  132. KOSUNEN TU, Nieminen AA, Kokkola A, Arkkila P, et al
    Incidence of gastrointestinal malignancies increases in persons received eradication therapy for Helicobacter pylori: A cohort study.
    Helicobacter. 2023 Apr 3:e12979. doi: 10.1111/hel.12979.
    PubMed     Abstract available


  133. COLLIN A, Mion F, Kefleyesus A, Beets C, et al
    Critical appraisal of international guidelines for the management of Helicobacter pylori infection in case of dyspepsia.
    Helicobacter. 2023;28:e12952.
    PubMed     Abstract available


    March 2023
  134. XIE Y, Hu Y, Zhu Y, Wang H, et al
    Colloidal bismuth pectin-containing quadruple therapy as the first-line treatment of Helicobacter pylori infection: A multicenter, randomized, double-blind, non-inferiority clinical trial.
    Helicobacter. 2023 Mar 31:e12978. doi: 10.1111/hel.12978.
    PubMed     Abstract available


  135. KWON YM, Kim SJ, Lee JG, Lee SP, et al
    Effects of prior antibiotic use on clarithromycin resistance in Helicobacter pylori.
    Helicobacter. 2023 Mar 28:e12974. doi: 10.1111/hel.12974.
    PubMed     Abstract available


  136. SUN L, Zheng H, Qiu M, Hao S, et al
    Helicobacter pylori infection and risk of cardiovascular disease.
    Helicobacter. 2023 Mar 28:e12967. doi: 10.1111/hel.12967.
    PubMed     Abstract available


  137. LYU T, Cheung KS, Deng Z, Ni L, et al
    Whole genome sequencing reveals novel genetic mutations of Helicobacter pylori associating with resistance to clarithromycin and levofloxacin.
    Helicobacter. 2023 Mar 25:e12972. doi: 10.1111/hel.12972.
    PubMed     Abstract available


  138. IKEDA N, Shoji H, Ikuse T, Ohkawa N, et al
    A case of neonatal thrombocytopenia due to maternal Helicobacter pylori-associated immune thrombocytopenia.
    Helicobacter. 2023 Mar 23:e12976. doi: 10.1111/hel.12976.
    PubMed     Abstract available


  139. KIM SB, Kim N, Park J, Hwang IC, et al
    Preventive effect of Helicobacter pylori eradication on the coronary heart diseases depending on age and sex with a median follow-up of 51 months.
    Helicobacter. 2023 Mar 22:e12969. doi: 10.1111/hel.12969.
    PubMed     Abstract available


  140. ERGENC M, Uprak TK
    YouTube as a source of information on Helicobacter pylori: Content and quality analysis.
    Helicobacter. 2023 Mar 21:e12971. doi: 10.1111/hel.12971.
    PubMed     Abstract available


  141. SHENG C, Sun L, Lyu Z, Li L, et al
    Development of a modified ABC method among Helicobacter pylori infected but serum pepsinogen test-negative individuals.
    Helicobacter. 2023 Mar 20:e12966. doi: 10.1111/hel.12966.
    PubMed     Abstract available


  142. ANTUNES R, Oleastro M, Nogueira JP, Lopes AI, et al
    Time trend prevalence of helicobacter pylori infection and endoscopic findings in symptomatic children in Portugal: A retrospective study based on three time points in 2009, 2014, and 2019.
    Helicobacter. 2023 Mar 10:e12963. doi: 10.1111/hel.12963.
    PubMed     Abstract available


  143. YU T, Lu T, Deng W, Yao D, et al
    Microbiome and function alterations in the gastric mucosa of asymptomatic patients with Helicobacter pylori infection.
    Helicobacter. 2023 Mar 8:e12965. doi: 10.1111/hel.12965.
    PubMed     Abstract available


    February 2023
  144. REN X, Shi Y, Suo B, Yao X, et al
    Individualized diagnosis and eradication therapy for Helicobacter pylori infection based on gene detection of clarithromycin resistance in stool specimens: A systematic review and meta-analysis.
    Helicobacter. 2023 Feb 24:e12958. doi: 10.1111/hel.12958.
    PubMed     Abstract available


  145. KAJIHARA Y, Shimoyama T, Mizuki I
    Evaluation of the effects of a proton pump inhibitor on Helicobacter pylori stool antigen testing.
    Helicobacter. 2023 Feb 24:e12961. doi: 10.1111/hel.12961.
    PubMed     Abstract available


  146. ARINO-PEREZ I, Martinez-Dominguez SJ, Alfaro Almajano E, Carrera-Lasfuentes P, et al
    Mistakes in the diagnosis and treatment of Helicobacter pylori infection in daily clinical practice.
    Helicobacter. 2023 Feb 24:e12957. doi: 10.1111/hel.12957.
    PubMed     Abstract available


  147. HE T, Zhang F, Zhang J, Wei S, et al
    UreB immunodominant epitope-specific CD8(+) T-cell responses were beneficial in reducing gastric symptoms in Helicobacter pylori-infected individuals.
    Helicobacter. 2023 Feb 24:e12959. doi: 10.1111/hel.12959.
    PubMed     Abstract available


  148. MACEDO SILVA V, Lima Capela T, Freitas M, Boal Carvalho P, et al
    A "new" option in Helicobacter pylori eradication: High-dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting.
    Helicobacter. 2023 Feb 24:e12962. doi: 10.1111/hel.12962.
    PubMed     Abstract available


  149. ZHAI K, Gong Y, Sun L, He L, et al
    DNA starvation/stationary phase protection protein of Helicobacter pylori as a potential immunodominant antigen for infection detection.
    Helicobacter. 2023 Feb 12:e12955. doi: 10.1111/hel.12955.
    PubMed     Abstract available


  150. ZHANG Y, Suo B, Tian X, Zhang H, et al
    New regimens as first-line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trial.
    Helicobacter. 2023 Feb 8:e12956. doi: 10.1111/hel.12956.
    PubMed     Abstract available


  151. BAILEY KS, Brown HE, Lekic V, Pradeep K, et al
    Helicobacter pylori treatment knowledge, access and barriers: A cross-sectional study.
    Helicobacter. 2023 Feb 7:e12954. doi: 10.1111/hel.12954.
    PubMed     Abstract available


  152. GUAN JL, Han YY, Wang MR, Xia SH, et al
    Impact of body size on efficacy of high-dose dual therapy for Helicobacter pylori eradication.
    Helicobacter. 2023 Feb 3:e12953. doi: 10.1111/hel.12953.
    PubMed     Abstract available


    January 2023
  153. HASSUNA NA, Hussien SS, Abdelhakeem M, Aboalela A, et al
    Regulatory B cells (Bregs) in Helicobacter pylori chronic infection.
    Helicobacter. 2023 Jan 20:e12951. doi: 10.1111/hel.12951.
    PubMed     Abstract available


  154. GAO W, Xu Y, Liu J, Wang X, et al
    A real-world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy or failed in previous amoxicillin-containing therapies.
    Helicobacter. 2023 Jan 17:e12947. doi: 10.1111/hel.12947.
    PubMed     Abstract available


  155. HAN Z, Liu J, Zhang W, Kong Q, et al
    Cardia and non-cardia gastric cancer risk associated with Helicobacter pylori in East Asia and the West: A systematic review, meta-analysis, and estimation of population attributable fraction.
    Helicobacter. 2023 Jan 16:e12950. doi: 10.1111/hel.12950.
    PubMed     Abstract available


  156. WANG Y, Dai X, Gao C, Yang X, et al
    Network meta-analysis of different dosages of esomeprazole and rabeprazole for the treatment of Helicobacter pylori.
    Helicobacter. 2023 Jan 16:e12948. doi: 10.1111/hel.12948.
    PubMed     Abstract available


  157. DUAN M, Li Y, Liu J, Zhang W, et al
    Transmission routes and patterns of helicobacter pylori.
    Helicobacter. 2023 Jan 16:e12945. doi: 10.1111/hel.12945.
    PubMed     Abstract available


  158. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Persistent advanced periductal fibrosis is and helicobacter pylori infection in post-treatment of opisthorchiasis: Correspondence.
    Helicobacter. 2023 Jan 12:e12949. doi: 10.1111/hel.12949.
    PubMed    


  159. ZHANG W, Gui Q, Chen J, Yu D, et al
    Intravenous metronidazole-, levofloxacin-containing triple therapy for treating patients with Helicobacter pylori-related active peptic ulcer complications: A pilot study.
    Helicobacter. 2023 Jan 12:e12946. doi: 10.1111/hel.12946.
    PubMed     Abstract available


  160. AMALIA R, Panenggak NSR, Doohan D, Rezkitha YAA, et al
    A comprehensive evaluation of an animal model for Helicobacter pylori-associated stomach cancer: Fact and controversy.
    Helicobacter. 2023 Jan 10:e12943. doi: 10.1111/hel.12943.
    PubMed     Abstract available


    December 2022
  161. ZHENG SY, Zhu L, Wu LY, Liu HR, et al
    Helicobacter pylori-positive chronic atrophic gastritis and cellular senescence.
    Helicobacter. 2022 Dec 20:e12944. doi: 10.1111/hel.12944.
    PubMed     Abstract available


  162. HAN Z, Li Y, Li Y
    Helicobacter pylori, gastrointestinal microbiota, and immunotherapy.
    Helicobacter. 2022 Dec 7:e12942. doi: 10.1111/hel.12942.
    PubMed    


  163. LEE JW, Kim N, Choi SI, Jang JY, et al
    Prevalence and trends of multiple antimicrobial resistance of Helicobacter pylori in one tertiary hospital for 20 years in Korea.
    Helicobacter. 2022 Dec 7:e12939. doi: 10.1111/hel.12939.
    PubMed     Abstract available


  164. RAMESH P, Babu S, Ammankallu S, Codi JAK, et al
    Helicobacter pylori regulated microRNA map of human gastric cells.
    Helicobacter. 2022 Dec 5:e12941. doi: 10.1111/hel.12941.
    PubMed     Abstract available


  165. ROKKAS T, Ekmektzoglou K, Graham DY
    Current role of tailored therapy in treating Helicobacter pylori infections. A systematic review, meta-analysis and critical analysis.
    Helicobacter. 2022 Dec 1:e12936. doi: 10.1111/hel.12936.
    PubMed     Abstract available


  166. LU L, Wang Y, Ye J, Han Y, et al
    Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
    Helicobacter. 2022 Dec 1:e12940. doi: 10.1111/hel.12940.
    PubMed     Abstract available


    November 2022
  167. YANG H, Mou Y, Hu B
    Discussion on the common controversies of Helicobacter pylori infection.
    Helicobacter. 2022 Nov 27:e12938. doi: 10.1111/hel.12938.
    PubMed     Abstract available


  168. JI YH, Shi YM, Hei QW, Sun JM, et al
    Evaluation of guidelines for diagnosis and treatment of Helicobacter pylori infection.
    Helicobacter. 2022 Nov 21:e12937. doi: 10.1111/hel.12937.
    PubMed     Abstract available


  169. TIAN XL, Suo BJ, Zhang H, Lu HP, et al
    Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
    Helicobacter. 2022 Nov 14:e12935. doi: 10.1111/hel.12935.
    PubMed     Abstract available


    October 2022
  170. HARA D, Okamura T, Iwaya Y, Nagaya T, et al
    Histopathologically defined intestinal metaplasia in lesser curvature of corpus prior to Helicobacter pylori eradication is a risk factor for gastric cancer development.
    Helicobacter. 2022 Oct 20:e12934. doi: 10.1111/hel.12934.
    PubMed     Abstract available


  171. TSUDA M, Watanabe Y, Oikawa R, Watanabe R, et al
    Clinical evaluation of a novel molecular diagnosis kit for detecting Helicobacter pylori and clarithromycin-resistant using intragastric fluid.
    Helicobacter. 2022 Oct 20:e12933. doi: 10.1111/hel.12933.
    PubMed     Abstract available


    September 2022
  172. CHUAH YY, Wu DC, Chuah SK, Chen KY, et al
    REAP-HP survey 2020: Comparing the real-world practice and expectation in Helicobacter pylori eradication of the Taiwanese gastroenterologists in 2015 and 2020.
    Helicobacter. 2022 Sep 25:e12931. doi: 10.1111/hel.12931.
    PubMed     Abstract available


  173. HAN Z, Li Y, Kong Q, Liu J, et al
    Efficacy of bismuth for antibiotic-resistant Helicobacter pylori strains eradication: A systematic review and meta-analysis.
    Helicobacter. 2022 Sep 25:e12930. doi: 10.1111/hel.12930.
    PubMed     Abstract available


  174. ZHANG Y, Li X, Shan B, Zhang H, et al
    Perspectives from recent advances of Helicobacter pylori vaccines research.
    Helicobacter. 2022 Sep 22:e12926. doi: 10.1111/hel.12926.
    PubMed     Abstract available


  175. AZRAD M, Vazana D, On A, Paritski M, et al
    Antibiotic resistance patterns of Helicobacter pylori in North Israel - A six-year study.
    Helicobacter. 2022 Sep 15:e12932. doi: 10.1111/hel.12932.
    PubMed     Abstract available


  176. CHOI S, Kim N, Park JH, Nam RH, et al
    Effect of Helicobacter pylori infection and its eradication on the expression of tight junction proteins in the gastric epithelium in relation to gastric carcinogenesis.
    Helicobacter. 2022 Sep 5:e12929. doi: 10.1111/hel.12929.
    PubMed     Abstract available


    August 2022
  177. ARJMANDI D, Abdollahi A, Ardekani A, Razavian I, et al
    Helicobacter pylori infection and risk of multiple sclerosis: An updated meta-analysis.
    Helicobacter. 2022 Aug 31:e12927. doi: 10.1111/hel.12927.
    PubMed     Abstract available


  178. WERNLY S, Semmler G, Volkerer A, Flamm M, et al
    Helicobacter pylori and cardiovascular risk: Only a dead Helicobacter is a good Helicobacter?
    Helicobacter. 2022 Aug 31:e12928. doi: 10.1111/hel.12928.
    PubMed     Abstract available


  179. SHI Y, Zheng H, Guo Z, Deng R, et al
    Effect of Helicobacter pylori on immunotherapy is gaining more attention.
    Helicobacter. 2022 Aug 29:e12925. doi: 10.1111/hel.12925.
    PubMed     Abstract available


  180. HU Y, Xu X, Ouyang YB, He C, et al
    Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication.
    Helicobacter. 2022 Aug 29:e12923. doi: 10.1111/hel.12923.
    PubMed     Abstract available


  181. BORDIN D, Morozov S, Plavnik R, Bakulina N, et al
    Helicobacter pylori infection prevalence in ambulatory settings in 2017-2019 in RUSSIA: The data of real-world national multicenter trial.
    Helicobacter. 2022 Aug 16:e12924. doi: 10.1111/hel.12924.
    PubMed     Abstract available


  182. TANAKA I, Ono S, Watanabe Y, Yamamoto H, et al
    Long-term changes in aberrant DNA methylation and gastritis after Helicobacter pylori eradication focused on metachronous gastric cancer.
    Helicobacter. 2022 Aug 8:e12915. doi: 10.1111/hel.12915.
    PubMed     Abstract available


  183. HAN YY, Long H, Lin Y, He Q, et al
    Optimized dual therapy for treatment-naive patients of Helicobacter pylori infection: A large-scale prospective, multicenter, open-label, randomized controlled study.
    Helicobacter. 2022 Aug 8. doi: 10.1111/hel.12922.
    PubMed     Abstract available


  184. SHAO Y, Lin Y, Wang B, Miao M, et al
    Antibiotic resistance status of helicobacter pylori strains isolated from initial eradication patients in Ningbo, China, from 2017 to 2021.
    Helicobacter. 2022 Aug 8:e12920. doi: 10.1111/hel.12920.
    PubMed     Abstract available


  185. ZHONG Z, Zhan B, Xu B, Gao H, et al
    Achieving Helicobacter pylori eradication in the primary treatment requires a deep integration of personalization and standardization.
    Helicobacter. 2022 Aug 8:e12916. doi: 10.1111/hel.12916.
    PubMed    


  186. INAMASU Y, Ogawa M, Saito M, Harada M, et al
    Helicobacter pylori results in lysis and death after exposure to water.
    Helicobacter. 2022 Aug 8:e12921. doi: 10.1111/hel.12921.
    PubMed     Abstract available


    July 2022
  187. MUNIR M, LeMaitre B, Lobo Z, Psevdos G, et al
    A 15-year review of Helicobacter pylori screening and treatment among United States Veterans.
    Helicobacter. 2022 Jul 28:e12919. doi: 10.1111/hel.12919.
    PubMed    


  188. MOMMERSTEEG MC, Yu BT, van den Bosch TPP, von der Thusen JH, et al
    Constitutive programmed death ligand 1 expression protects gastric G-cells from Helicobacter pylori-induced inflammation.
    Helicobacter. 2022 Jul 28:e12917. doi: 10.1111/hel.12917.
    PubMed     Abstract available


  189. GAO W, Teng G, Wang C, Xu Y, et al
    Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study i
    Helicobacter. 2022 Jul 25:e12918. doi: 10.1111/hel.12918.
    PubMed     Abstract available


  190. CHEN MJ, Bair MJ, Chen PY, Lee JY, et al
    Declining trends of prevalence of Helicobacter pylori infection and incidence of gastric cancer in Taiwan: An updated cross-sectional survey and meta-analysis.
    Helicobacter. 2022 Jul 18:e12914. doi: 10.1111/hel.12914.
    PubMed     Abstract available


  191. SUKRI A, Hanafiah A, Kosai NR, Mohammed Taher M, et al
    New insight on the role of Helicobacter pylori cagA in the expression of cell surface antigens with important biological functions in gastric carcinogenesis.
    Helicobacter. 2022 Jul 18:e12913. doi: 10.1111/hel.12913.
    PubMed     Abstract available


  192. KONG Q, Li Y, Li R, Li Z, et al
    Low compliance to post-screening recommendations in a family-based Helicobacter pylori screening and treatment program: A prospective cohort study.
    Helicobacter. 2022 Jul 11:e12912. doi: 10.1111/hel.12912.
    PubMed     Abstract available


    June 2022
  193. MA J, Yu M, Shao QQ, Yu XC, et al
    Both family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are cost-effective for gastric cancer prevention.
    Helicobacter. 2022 Jun 15:e12911. doi: 10.1111/hel.12911.
    PubMed     Abstract available


  194. SOUISSI S, Makni C, Belhadj Ammar L, Bousnina O, et al
    Correlation between the intensity of Helicobacter pylori colonization and severity of gastritis: Results of a prospective study.
    Helicobacter. 2022 Jun 13:e12910. doi: 10.1111/hel.12910.
    PubMed     Abstract available


  195. XIAO W, Ma ZS
    Influences of Helicobacter pylori infection on diversity, heterogeneity, and composition of human gastric microbiomes across stages of gastric cancer development.
    Helicobacter. 2022 Jun 9:e12899. doi: 10.1111/hel.12899.
    PubMed     Abstract available


    May 2022
  196. INOKUCHI K, Mori H, Matsuzaki J, Hirata K, et al
    Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen.
    Helicobacter. 2022 May 29:e12900. doi: 10.1111/hel.12900.
    PubMed     Abstract available


  197. AKAR M, Saticioglu IB, Karakaya E, Kayman T, et al
    Two novel sequence types of Helicobacter pylori strains: The first report from Turkey.
    Helicobacter. 2022 May 23:e12907. doi: 10.1111/hel.12907.
    PubMed    


  198. HE C, Peng C, Xu X, Li N, et al
    Probiotics mitigate Helicobacter pylori-induced gastric inflammation and premalignant lesions in INS-GAS mice with the modulation of gastrointestinal microbiota.
    Helicobacter. 2022 May 9:e12898. doi: 10.1111/hel.12898.
    PubMed     Abstract available


  199. PHUNG HTT, Deenonpoe R, Suttiprapa S, Mairiang E, et al
    Persistent advanced periductal fibrosis is associated with cagA-positive Helicobacter pylori infection in post-praziquantel treatment of opisthorchiasis.
    Helicobacter. 2022 May 9:e12897. doi: 10.1111/hel.12897.
    PubMed     Abstract available


    April 2022
  200. SAIF N, Jensen N, Farrar E, Blackstone S, et al
    Prevalence of Helicobacter pylori infection among resettled refugees presenting to a family medicine clinic in the United States.
    Helicobacter. 2022 Apr 28:e12894. doi: 10.1111/hel.12894.
    PubMed     Abstract available


  201. HU Y, Xu X, Ouyang YB, He C, et al
    Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study.
    Helicobacter. 2022 Apr 25:e12896. doi: 10.1111/hel.12896.
    PubMed     Abstract available


  202. LI C, Lu C, Gong L, Liu J, et al
    SHP2/SPI1axis promotes glycolysis and the inflammatory response of macrophages in Helicobacter pylori-induced pediatric gastritis.
    Helicobacter. 2022 Apr 19:e12895. doi: 10.1111/hel.12895.
    PubMed     Abstract available


  203. JIANG F, Guo CG, Cheung KS, Li B, et al
    Age of eradication and failure rates of clarithromycin-containing triple therapy for Helicobacter pylori: A 15-year population-based study.
    Helicobacter. 2022 Apr 12:e12893. doi: 10.1111/hel.12893.
    PubMed     Abstract available


  204. CHUA BQY, Chong VWS, Teng TZJ, Chia CTW, et al
    Does technology-enhanced communication improve Helicobacter pylori eradication outcomes?-A meta-analysis.
    Helicobacter. 2022 Apr 1:e12890. doi: 10.1111/hel.12890.
    PubMed     Abstract available


  205. SONG Z, Chen Y, Lu H, Zeng Z, et al
    Diagnosis and treatment of Helicobacter pylori infection by physicians in China: A nationwide cross-sectional study.
    Helicobacter. 2022 Apr 1:e12889. doi: 10.1111/hel.12889.
    PubMed     Abstract available


    March 2022
  206. KOWADA A, Asaka M
    Economic and health impacts of Helicobacter pylori eradication strategy for the treatment of peptic ulcer disease: A cost-effectiveness analysis.
    Helicobacter. 2022 Mar 27:e12886. doi: 10.1111/hel.12886.
    PubMed     Abstract available


  207. HSIEH H, Yang HB, Sheu BS, Yang YJ, et al
    Atrophic gastritis in Helicobacter pylori-infected children.
    Helicobacter. 2022 Mar 20:e12885. doi: 10.1111/hel.12885.
    PubMed     Abstract available


  208. POLIVANOVA TV, Malaty H, Vshivkov VA
    Epidemiology Helicobacter pylori infection in children in the Tyva Republic (Russia).
    Helicobacter. 2022 Mar 13:e12882. doi: 10.1111/hel.12882.
    PubMed     Abstract available


  209. KOUNTOURAS J, Kazakos E, Polyzos SA, Chatzopoulos D, et al
    GM-CSF as a potential candidate of a vaccine-induced reduction of Helicobacter pylori infection.
    Helicobacter. 2022 Mar 7:e12884. doi: 10.1111/hel.12884.
    PubMed    


  210. YOKOTA K, Osaki T, Hayashi S, Yokota SI, et al
    Establishment of a reference panel of Helicobacter pylori strains for antimicrobial susceptibility testing.
    Helicobacter. 2022 Mar 7:e12874. doi: 10.1111/hel.12874.
    PubMed     Abstract available


  211. MORAIS S, Costa A, Albuquerque G, Araujo N, et al
    "True" Helicobacter pylori infection and non-cardia gastric cancer: A pooled analysis within the Stomach Cancer Pooling (StoP) Project.
    Helicobacter. 2022 Mar 2:e12883. doi: 10.1111/hel.12883.
    PubMed     Abstract available


    February 2022
  212. EL HAFA F, Wang T, Ndifor VM, Jin G, et al
    Association between Helicobacter pylori antibodies determined by multiplex serology and gastric cancer risk: A meta-analysis.
    Helicobacter. 2022 Feb 24:e12881. doi: 10.1111/hel.12881.
    PubMed     Abstract available


  213. ZHOU BG, Yan XL, Wan LY, Zhang Q, et al
    Effect of enhanced patient instructions on Helicobacter pylori eradication: A systematic review and meta-analysis of randomized controlled trials.
    Helicobacter. 2022 Feb 18:e12869. doi: 10.1111/hel.12869.
    PubMed     Abstract available


  214. LI H, Shen Y, Song X, Tang X, et al
    Need for standardization and harmonization of Helicobacter pylori antimicrobial susceptibility testing.
    Helicobacter. 2022 Feb 12:e12873. doi: 10.1111/hel.12873.
    PubMed     Abstract available


  215. ZHA J, Li YY, Qu JY, Yang XX, et al
    Effects of enhanced education for patients with the Helicobacter pylori infection: A systematic review and meta-analysis.
    Helicobacter. 2022 Feb 12:e12880. doi: 10.1111/hel.12880.
    PubMed     Abstract available


  216. SHAO QQ, Yu XC, Yu M, Ma J, et al
    Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial.
    Helicobacter. 2022 Feb 12:e12876. doi: 10.1111/hel.12876.
    PubMed     Abstract available


  217. LI Y, Huang Z, Shang Y, Xie X, et al
    Exploration of the molecular mechanisms underlying the antibiotic resistance of Helicobacter pylori: A whole-genome sequencing-based study in Southern China.
    Helicobacter. 2022 Feb 6:e12879. doi: 10.1111/hel.12879.
    PubMed     Abstract available


  218. SHI Y, Zheng H, Wang M, Ding S, et al
    Influence of Helicobacter pylori infection on PD-1/PD-L1 blockade therapy needs more attention.
    Helicobacter. 2022 Feb 3:e12878. doi: 10.1111/hel.12878.
    PubMed     Abstract available


    January 2022
  219. QIANG L, Hu J, Tian M, Li Y, et al
    Extracellular vesicles from helicobacter pylori-infected cells and helicobacter pylori outer membrane vesicles in atherosclerosis.
    Helicobacter. 2022 Jan 31:e12877. doi: 10.1111/hel.12877.
    PubMed     Abstract available


  220. VAILLANT L, Oster P, McMillan B, Orozco Fernandez E, et al
    GM-CSF is key in the efficacy of vaccine-induced reduction of Helicobacter pylori infection.
    Helicobacter. 2022 Jan 29:e12875. doi: 10.1111/hel.12875.
    PubMed     Abstract available


  221. DI MARIO F, Crafa P, Barchi A, Franzoni L, et al
    Pepsinogen II in gastritis and Helicobacter pylori infection.
    Helicobacter. 2022 Jan 8:e12872. doi: 10.1111/hel.12872.
    PubMed     Abstract available


  222. XU C, Wu Y, Xu S
    Association between Helicobacter pylori infection and growth outcomes in children: A meta-analysis.
    Helicobacter. 2022 Jan 8:e12861. doi: 10.1111/hel.12861.
    PubMed     Abstract available


  223. CIFUENTES SG, Prado MB, Fornasini M, Cohen H, et al
    Saccharomyces boulardii CNCM I-745 supplementation modifies the fecal resistome during Helicobacter pylori eradication therapy.
    Helicobacter. 2022 Jan 6:e12870. doi: 10.1111/hel.12870.
    PubMed     Abstract available


    December 2021
  224. WANG L, Yao H, Tong T, Lau K, et al
    Dynamic changes in antibiotic resistance genes and gut microbiota after Helicobacter pylori eradication therapies.
    Helicobacter. 2021 Dec 30:e12871. doi: 10.1111/hel.12871.
    PubMed     Abstract available


  225. HUANG JG, Lim SYS, Aw MM, Quak SH, et al
    Antibiotic resistance patterns and therapeutic outcomes of pediatric Helicobacter pylori infection in a high-migrant Singaporean cohort.
    Helicobacter. 2021 Dec 27:e12868. doi: 10.1111/hel.12868.
    PubMed     Abstract available


    November 2021
  226. SHI H, Li Y, Dong C, Si G, et al
    Helicobacter pylori infection and the progression of atherosclerosis: A systematic review and meta-analysis.
    Helicobacter. 2021 Nov 28:e12865. doi: 10.1111/hel.12865.
    PubMed     Abstract available


  227. FERREIRA EO, Lagace-Wiens P, Klein J
    Campylobacter concisus gastritis masquerading as Helicobacter pylori on gastric biopsy.
    Helicobacter. 2021 Nov 24:e12864. doi: 10.1111/hel.12864.
    PubMed     Abstract available


  228. MURATA M, Sugimoto M, Miyamoto S, Kawai T, et al
    Long-term improvement in constipation-related symptoms after Helicobacter pylori eradication therapy.
    Helicobacter. 2021 Nov 17:e12863. doi: 10.1111/hel.12863.
    PubMed     Abstract available


  229. ZAGARI RM, Romano M, Frazzoni L, Marasco G, et al
    Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy: A Survey of the Italian Federation of Digestive Diseases - FISMAD.
    Helicobacter. 2021 Nov 11:e12862. doi: 10.1111/hel.12862.
    PubMed     Abstract available


    October 2021
  230. YU J, Yang P, Qin X, Li C, et al
    Impact of smoking on the eradication of Helicobacter pylori.
    Helicobacter. 2021 Oct 27:e12860. doi: 10.1111/hel.12860.
    PubMed     Abstract available


  231. CHEN MJ, Chen CC, Huang YC, Tseng CC, et al
    The efficacy of Lactobacillus acidophilus and rhamnosus in the reduction of bacterial load of Helicobacter pylori and modification of gut microbiota-a double-blind, placebo-controlled, randomized trial.
    Helicobacter. 2021 Oct 27:e12857. doi: 10.1111/hel.12857.
    PubMed     Abstract available


  232. YANG C, Liang L, Lv P, Liu L, et al
    Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: A randomized double-blind placebo-controlled trial.
    Helicobacter. 2021 Oct 10:e12856. doi: 10.1111/hel.12856.
    PubMed     Abstract available


  233. BENEJAT L, Ducournau A, Domingues-Martins C, Lecoeur M, et al
    Adaptation of an in-house PCR for the detection of Helicobacter pylori and the mutations associated with macrolide resistance into ready-to-use PCR microwell strips.
    Helicobacter. 2021 Oct 10:e12855. doi: 10.1111/hel.12855.
    PubMed     Abstract available


  234. LAPIDOT Y, Reshef L, Cohen D, Muhsen K, et al
    Helicobacter pylori and the intestinal microbiome among healthy school-age children.
    Helicobacter. 2021 Oct 7:e12854. doi: 10.1111/hel.12854.
    PubMed     Abstract available


    September 2021
  235. VARMA M, Yoe J
    Importance of testing for Helicobacter pylori in patients with immune thrombocytopenia.
    Helicobacter. 2021 Sep 22:e12850. doi: 10.1111/hel.12850.
    PubMed    


  236. LUCERO Y, Lagomarcino AJ, Torres JP, Roessler P, et al
    Effect of Helicobacter pylori eradication therapy on clinical and laboratory biomarkers associated with gastric damage in healthy school-aged children: A randomized non-blinded trial.
    Helicobacter. 2021 Sep 15:e12853. doi: 10.1111/hel.12853.
    PubMed     Abstract available


  237. ZHAO H, Yan P, Zhang N, Feng L, et al
    The recurrence rate of Helicobacter pylori in recent 10 years: A systematic review and meta-analysis.
    Helicobacter. 2021 Sep 12:e12852. doi: 10.1111/hel.12852.
    PubMed     Abstract available


  238. CHEN HY, Hu Y, Xu XB, Zhou YA, et al
    Upregulation of oncogene Activin A receptor type I by Helicobacter pylori infection promotes gastric intestinal metaplasia via regulating CDX2.
    Helicobacter. 2021 Sep 7:e12849. doi: 10.1111/hel.12849.
    PubMed     Abstract available


  239. SUZUKI S, Gotoda T, Takano C, Horii T, et al
    Long term impact of vonoprazan-based Helicobacter pylori treatment on gut microbiota and its relation to post-treatment body weight changes.
    Helicobacter. 2021 Sep 6:e12851. doi: 10.1111/hel.12851.
    PubMed     Abstract available


    August 2021
  240. YUAN Z, Xiao S, Li S, Suo B, et al
    The impact of Helicobacter pylori infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults.
    Helicobacter. 2021 Aug 26:e12848. doi: 10.1111/hel.12848.
    PubMed     Abstract available


  241. YAO X, Xiao S, Zhou L
    Integrative proteomic and metabolomic analyses reveal the mechanism by which bismuth enables Helicobacter pylori eradication.
    Helicobacter. 2021 Aug 20:e12846. doi: 10.1111/hel.12846.
    PubMed     Abstract available


  242. LEE JW, Kim N, Nam RH, Jang JY, et al
    Favorable outcomes of rescue second- or third-line culture-based Helicobacter pylori eradication treatment in areas of high antimicrobial resistance.
    Helicobacter. 2021 Aug 12:e12844. doi: 10.1111/hel.12844.
    PubMed     Abstract available


  243. HSU PI, Tsay FW, Kao JY, Peng NJ, et al
    Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection.
    Helicobacter. 2021 Aug 12:e12840. doi: 10.1111/hel.12840.
    PubMed     Abstract available


  244. GUO R, Wu S, Guan L, Xie Y, et al
    Dietary multivalent anti-Helicobacter pylori immunoglobulin Y significantly increase the H. pylori eradication and improve the clinical symptoms in patients.
    Helicobacter. 2021 Aug 11:e12843. doi: 10.1111/hel.12843.
    PubMed     Abstract available


    July 2021
  245. GONG L, El-Omar EM
    Application of molecular techniques in Helicobacter pylori detection: limitations and improvements.
    Helicobacter. 2021 Jul 31:e12841. doi: 10.1111/hel.12841.
    PubMed    


  246. OUYANG Y, Zhang W, Huang Y, Wang Y, et al
    Effect of Helicobacter pylori eradication on hyperplastic gastric polyps: A systematic review and meta-analysis.
    Helicobacter. 2021 Jul 31:e12838. doi: 10.1111/hel.12838.
    PubMed     Abstract available


  247. LI N, Xu X, Yang H, Wang H, et al
    Activation of Aquaporin 5 by carcinogenic Helicobacter pylori infection promotes epithelial-mesenchymal transition via the MEK/ERK pathway.
    Helicobacter. 2021 Jul 30:e12842. doi: 10.1111/hel.12842.
    PubMed     Abstract available


  248. ZHAO J, Zou Y, Li K, Huang X, et al
    Doxycycline and minocycline in Helicobacter pylori treatment: A systematic review and meta-analysis.
    Helicobacter. 2021 Jul 28:e12839. doi: 10.1111/hel.12839.
    PubMed     Abstract available


  249. ZOU PY, Hu J, Zhao JT, Zhao Z, et al
    10-Day and 14-day high-dose dual therapy for the treatment of Helicobacter pylori: A propensity score matching analysis.
    Helicobacter. 2021 Jul 28:e12833. doi: 10.1111/hel.12833.
    PubMed     Abstract available


  250. KOWADA A, Asaka M
    Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: A cost-effectiveness analysis.
    Helicobacter. 2021 Jul 18:e12837. doi: 10.1111/hel.12837.
    PubMed     Abstract available


  251. GUNATHILAKE M, Lee J, Choi IJ, Kim YI, et al
    Association between bacteria other than Helicobacter pylori and the risk of gastric cancer.
    Helicobacter. 2021 Jul 15:e12836. doi: 10.1111/hel.12836.
    PubMed     Abstract available


  252. OUYANG Y, Zhu Z, Huang L, Zeng C, et al
    Research Trends on Clinical Helicobacter pylori Eradication: A Bibliometric Analysis from 1983 to 2020.
    Helicobacter. 2021 Jul 13:e12835. doi: 10.1111/hel.12835.
    PubMed     Abstract available


  253. GUNARATNE AW, Hamblin H, Clancy A, Magat AJMC, et al
    Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study.
    Helicobacter. 2021 Jul 10:e12830. doi: 10.1111/hel.12830.
    PubMed     Abstract available


  254. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    cagA+ Helicobacter pylori infection and N-nitrosodimethylamine and cholangiocarcinoma.
    Helicobacter. 2021 Jul 8:e12834. doi: 10.1111/hel.12834.
    PubMed    


  255. MA H, Zhao XH, Zhang LL, Wu LM, et al
    Application of WeChat platform in the management of patients infected with Helicobacter pylori.
    Helicobacter. 2021 Jul 7:e12832. doi: 10.1111/hel.12832.
    PubMed     Abstract available


  256. HE Y, Ning J, Li B, Guo H, et al
    IL-9 contributes to the host immune response against Helicobacter pylori and helps limit infection in a Mouse Model.
    Helicobacter. 2021 Jul 7:e12827. doi: 10.1111/hel.12827.
    PubMed     Abstract available


    June 2021
  257. TSAI CF, Chen MH, Wang YP, Liu PY, et al
    Increased risk of short-term depressive disorder after Helicobacter pylori eradication: A population-based nested cohort study.
    Helicobacter. 2021 Jun 11:e12824. doi: 10.1111/hel.12824.
    PubMed     Abstract available


  258. QIU E, Jin S, Xiao Z, Chen Q, et al
    CRISPR-based detection of Helicobacter pylori in stool samples.
    Helicobacter. 2021 Jun 11:e12828. doi: 10.1111/hel.12828.
    PubMed     Abstract available


  259. KOTILEA K, Cadranel S, Salame A, Nguyen J, et al
    Efficacy and safety of bismuth-based quadruple therapy for Helicobacter pylori eradication in children.
    Helicobacter. 2021 Jun 7:e12825. doi: 10.1111/hel.12825.
    PubMed     Abstract available


    May 2021
  260. MONZANI A, Lionetti P, Rabbone I, Lionetti E, et al
    The best is the enemy of the good: Time for a biopsy-sparing approach for Helicobacter pylori diagnosis and treatment in children in the COVID-19 era?
    Helicobacter. 2021 May 28:e12826. doi: 10.1111/hel.12826.
    PubMed    


  261. DANGTAKOT R, Intuyod K, Chamgramol Y, Pairojkul C, et al
    CagA(+) Helicobacter pylori infection and N-nitrosodimethylamine administration induce cholangiocarcinoma development in hamsters.
    Helicobacter. 2021 May 24:e12817. doi: 10.1111/hel.12817.
    PubMed     Abstract available


  262. LI C, Shi Y, Suo B, Tian X, et al
    PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta-analysis.
    Helicobacter. 2021 May 17:e12816. doi: 10.1111/hel.12816.
    PubMed     Abstract available


  263. TSUKADAIRA T, Hayashi S, Ota H, Kobayashi N, et al
    Acute gastric mucosal lesions caused by acute infection of non-Helicobacter pylori Helicobacter: a case report.
    Helicobacter. 2021 May 11:e12814. doi: 10.1111/hel.12814.
    PubMed     Abstract available


  264. ZHANG Z, Chen S, Fan M, Ruan G, et al
    Helicobacter pylori induces gastric cancer via down-regulating miR-375 to inhibit dendritic cell maturation.
    Helicobacter. 2021 May 3:e12813. doi: 10.1111/hel.12813.
    PubMed     Abstract available


    April 2021
  265. HERNANDEZ C, Toledo-Stuardo K, Garcia-Gonzalez P, Garrido-Tapia M, et al
    Heat-killed Helicobacter pylori upregulates NKG2D ligands expression on gastric adenocarcinoma cells via Toll-like receptor 4.
    Helicobacter. 2021 Apr 29:e12812. doi: 10.1111/hel.12812.
    PubMed     Abstract available


  266. TSUKADAIRA T, Hayashi S, Ota H, Kobayashi N, et al
    Prevalence, clinical features, and esophagogastroduodenoscopy (EGD) findings of non-Helicobacter pylori Helicobacter infection: A study of 50 cases at a single facility in Japan.
    Helicobacter. 2021 Apr 27:e12811. doi: 10.1111/hel.12811.
    PubMed     Abstract available


  267. WANG X, Shu X, Li Q, Li Y, et al
    Prevalence and risk factors of Helicobacter pylori infection in Wuwei, a high-risk area for gastric cancer in northwest China: An all-ages population-based cross-sectional study.
    Helicobacter. 2021 Apr 27:e12810. doi: 10.1111/hel.12810.
    PubMed     Abstract available


  268. ZHOU Y, Ye Z, Wang Y, Huang Z, et al
    Long-term changes in the gut microbiota after triple therapy, sequential therapy, bismuth quadruple therapy and concomitant therapy for Helicobacter pylori eradication in Chinese children.
    Helicobacter. 2021 Apr 25:e12809. doi: 10.1111/hel.12809.
    PubMed     Abstract available


  269. LI SY, Li J, Dong XH, Teng GG, et al
    The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing.
    Helicobacter. 2021 Apr 16:e12804. doi: 10.1111/hel.12804.
    PubMed     Abstract available


  270. XIE W, Zhao W, Zou Z, Kong L, et al
    Oral multivalent epitope vaccine, based on UreB, HpaA, CAT, and LTB, for prevention and treatment of Helicobacter pylori infection in C57BL / 6 mice.
    Helicobacter. 2021 Apr 12:e12807. doi: 10.1111/hel.12807.
    PubMed     Abstract available


  271. DO AD, Chang CC, Su CH, Hsu YM, et al
    Lactobacillus rhamnosus JB3 inhibits Helicobacter pylori infection through multiple molecular actions.
    Helicobacter. 2021 Apr 11:e12806. doi: 10.1111/hel.12806.
    PubMed     Abstract available


  272. TURNER KO, Lindberg GM, Genta RM
    Gastric granulomas and Helicobacter pylori: An incidental relationship.
    Helicobacter. 2021 Apr 11:e12805. doi: 10.1111/hel.12805.
    PubMed     Abstract available


  273. YORGUC E, Gulerman HF, Kalkan IH, Guven B, et al
    Comparison of clinical outcomes and FOXP3, IL-17A responses in Helicobacter pylori infection in children versus adults.
    Helicobacter. 2021 Apr 5:e12795. doi: 10.1111/hel.12795.
    PubMed     Abstract available


  274. KUBOTA-AIZAWA S, Matsubara Y, Kanemoto H, Mimuro H, et al
    Transmission of Helicobacter pylori between a human and two dogs: A case report.
    Helicobacter. 2021 Apr 5:e12798. doi: 10.1111/hel.12798.
    PubMed     Abstract available


    March 2021
  275. LI Y, Li X, Tan Z
    An overview of traditional Chinese medicine therapy for Helicobacter pylori-related gastritis.
    Helicobacter. 2021 Mar 25:e12799. doi: 10.1111/hel.12799.
    PubMed     Abstract available


  276. CHIANG TH, Chen CC, Tseng PH, Liou JM, et al
    Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study.
    Helicobacter. 2021 Mar 19:e12801. doi: 10.1111/hel.12801.
    PubMed     Abstract available


  277. HEFFLEY JD, Zubarik R
    A standardized protocol improves testing rates for Helicobacter Pylori among inpatients with peptic ulcer disease.
    Helicobacter. 2021 Mar 15:e12800. doi: 10.1111/hel.12800.
    PubMed     Abstract available


  278. MARUBASHI K, Takakusagi S, Yokoyama Y, Kizawa K, et al
    Changes of (18) F-fluoro-2-deoxyglucose position-emission tomography findings by the eradication of Helicobacter pylori in the stomach.
    Helicobacter. 2021 Mar 8:e12797. doi: 10.1111/hel.12797.
    PubMed     Abstract available


  279. ZHAO JB, Yuan L, Yu XC, Shao QQ, et al
    Whole family-based Helicobacter pylori eradication is a superior strategy to single-infected patient treatment approach: A systematic review and meta-analysis.
    Helicobacter. 2021 Mar 6:e12793. doi: 10.1111/hel.12793.
    PubMed     Abstract available


  280. JAIN U, Saxena K, Chauhan N
    Helicobacter pylori induced reactive oxygen Species: A new and developing platform for detection.
    Helicobacter. 2021 Mar 5:e12796. doi: 10.1111/hel.12796.
    PubMed     Abstract available


  281. TENG TZJ, Sudharsan M, Yau JWK, Tan W, et al
    Helicobacter pylori knowledge and perception among multi-ethnic Asians.
    Helicobacter. 2021 Mar 3:e12794. doi: 10.1111/hel.12794.
    PubMed     Abstract available


  282. KIM YJ, Chung WC, Kim DB
    Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection.
    Helicobacter. 2021 Mar 1:e12792. doi: 10.1111/hel.12792.
    PubMed     Abstract available


    February 2021
  283. HUANG Y, Ding Y, Xu H, Shen C, et al
    Effects of sodium butyrate supplementation on inflammation, gut microbiota, and short-chain fatty acids in Helicobacter pylori-infected mice.
    Helicobacter. 2021 Feb 20:e12785. doi: 10.1111/hel.12785.
    PubMed     Abstract available


  284. XIE M, Li Q, Zhang B, Zhang Q, et al
    Preliminary single-center experience of Helicobacter pylori eradication among the liver transplant recipients.
    Helicobacter. 2021 Feb 18:e12791. doi: 10.1111/hel.12791.
    PubMed     Abstract available


  285. GANTUYA B, El Serag HB, Saruuljavkhlan B, Azzaya D, et al
    Advantage of 16S rRNA amplicon sequencing in Helicobacter pylori diagnosis.
    Helicobacter. 2021 Feb 17:e12790. doi: 10.1111/hel.12790.
    PubMed     Abstract available


  286. LEE BE, Kim JS, Kim BW, Kim JH, et al
    Consistency of Helicobacter pylori eradication rates of first-line concomitant and sequential therapies in Korea: A nationwide multicenter retrospective study for the last 10 years.
    Helicobacter. 2021 Feb 17:e12780. doi: 10.1111/hel.12780.
    PubMed     Abstract available


  287. WU ZF, Zou K, Xiang CJ, Jin ZJ, et al
    Helicobacter pylori infection is associated with the co-occurrence of bacteria in the oral cavity and the gastric mucosa.
    Helicobacter. 2021 Feb 17:e12786. doi: 10.1111/hel.12786.
    PubMed     Abstract available


  288. YANG KY, Kao CY, Su MS, Wang S, et al
    Glycosyltransferase Jhp0106 (PseE) contributes to flagellin maturation in Helicobacter pylori.
    Helicobacter. 2021 Feb 15:e12787. doi: 10.1111/hel.12787.
    PubMed     Abstract available


  289. LACOUT C, Savey L, Bourguiba R, Giurgea I, et al
    "Helicobacter pylori in familial mediterranean fever: A series of 120 patients from literature and from france".
    Helicobacter. 2021 Feb 15:e12789. doi: 10.1111/hel.12789.
    PubMed     Abstract available


  290. ETO H, Suzuki S, Kusano C, Ikehara H, et al
    Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy.
    Helicobacter. 2021 Feb 12:e12788. doi: 10.1111/hel.12788.
    PubMed     Abstract available


  291. HU Y, Ouyang Y, Zhu Y, Lu NH, et al
    Reverse hybrid therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
    Helicobacter. 2021 Feb 3:e12784. doi: 10.1111/hel.12784.
    PubMed     Abstract available


    January 2021
  292. PARK Y, Kim TJ, Lee H, Yoo H, et al
    Eradication of Helicobacter pylori infection decreases risk for dyslipidemia: A cohort study.
    Helicobacter. 2021 Jan 28:e12783. doi: 10.1111/hel.12783.
    PubMed     Abstract available


  293. DOMANOVICH-ASOR T, Craddock HA, Motro Y, Khalfin B, et al
    Unraveling antimicrobial resistance in Helicobacter pylori: Global resistome meets global phylogeny.
    Helicobacter. 2021 Jan 25:e12782. doi: 10.1111/hel.12782.
    PubMed     Abstract available


  294. SONG X, Cai C, Jin Q, Chen X, et al
    The efficacy of Helicobacter pylori eradication in diabetics and its effect on glycemic control: A systematic review and meta-analysis.
    Helicobacter. 2021 Jan 19:e12781. doi: 10.1111/hel.12781.
    PubMed     Abstract available


  295. WEN Y, Huang H, Tang T, Yang H, et al
    AI-2 represses CagA expression and bacterial adhesion, attenuating the Helicobacter pylori-induced inflammatory response of gastric epithelial cells.
    Helicobacter. 2021 Jan 5:e12778. doi: 10.1111/hel.12778.
    PubMed     Abstract available


  296. MUNOZ AB, Trespalacios-Rangel AA, Vale FF
    An American lineage of Helicobacter pylori prophages found in Colombia.
    Helicobacter. 2021 Jan 5:e12779. doi: 10.1111/hel.12779.
    PubMed     Abstract available


  297. JUNG K, Kim DH, Seo HI, Gong EJ, et al
    Efficacy of eradication therapy in Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: A meta-analysis.
    Helicobacter. 2021 Jan 5:e12774. doi: 10.1111/hel.12774.
    PubMed     Abstract available


    December 2020
  298. XUE Q, Li X, Li Y, Xu J, et al
    Dialogue between gastrointestinal tract and skin: New insights into the Helicobacter pylori and atopic dermatitis.
    Helicobacter. 2020 Dec 23:e12771. doi: 10.1111/hel.12771.
    PubMed     Abstract available


  299. QARIA MA, Qumar S, Sepe LP, Ahmed N, et al
    Cholesterol glucosylation-based survival strategy in Helicobacter pylori.
    Helicobacter. 2020 Dec 23:e12777. doi: 10.1111/hel.12777.
    PubMed     Abstract available


  300. KAKIUCHI T, Matsuo M, Endo H, Sakata Y, et al
    Gastrointestinal adverse reactions reduce the success rate of Helicobacter pylori eradication therapy: A multicenter prospective cohort study.
    Helicobacter. 2020 Dec 23:e12776. doi: 10.1111/hel.12776.
    PubMed     Abstract available


  301. JUKIC I, Vukovic J, Rusic D, Bozic J, et al
    Adherence to Maastricht V/Florence consensus report for the management of Helicobacter pylori infection among primary care physicians and medical students in Croatia: A cross-sectional study.
    Helicobacter. 2020 Dec 23:e12775. doi: 10.1111/hel.12775.
    PubMed     Abstract available


  302. BANGA NDZOUBOUKOU JL, Lei Q, Ullah N, Zhang Y, et al
    Helicobacter pylori adhesins: HpaA a potential antigen in experimental vaccines for H. pylori.
    Helicobacter. 2020 Dec 1:e12758. doi: 10.1111/hel.12758.
    PubMed     Abstract available


    November 2020
  303. CEN Q, Gao T, Ren Y, Lu X, et al
    Immune evaluation of a Saccharomyces cerevisiae-based oral vaccine against Helicobacter pylori in mice.
    Helicobacter. 2020 Nov 20:e12772. doi: 10.1111/hel.12772.
    PubMed     Abstract available


  304. GRAHAM DY, Megraud F
    Classification system for Helicobacter pylori therapies: Compared and contrasted to traditional infectious disease therapy.
    Helicobacter. 2020 Nov 18:e12773. doi: 10.1111/hel.12773.
    PubMed    


  305. SINGH H, Chung H, Awan I, Mone A, et al
    Designing strategies for eradication of Helicobacter pylori based on prevalence patterns of infection and antibiotic resistance in a low-income, medically underserved community in the United States.
    Helicobacter. 2020 Nov 9:e12769. doi: 10.1111/hel.12769.
    PubMed     Abstract available


    October 2020
  306. PIH GY, Choi KD, Gong EJ, Na HK, et al
    Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection.
    Helicobacter. 2020 Oct 28:e12759. doi: 10.1111/hel.12759.
    PubMed     Abstract available


  307. MEGRAUD F, Alix C, Charron P, Benejat L, et al
    Survey of the antimicrobial resistance of Helicobacter pylori in France in 2018 and evolution during the previous 5 years.
    Helicobacter. 2020 Oct 22:e12767. doi: 10.1111/hel.12767.
    PubMed     Abstract available


  308. KE H, Li J, Lu B, Yang C, et al
    The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy.
    Helicobacter. 2020 Oct 21:e12768. doi: 10.1111/hel.12768.
    PubMed     Abstract available


  309. QUMAR S, Nguyen TH, Nahar S, Sarker N, et al
    A comparative whole genome analysis of Helicobacter pylori from a human dense South Asian setting.
    Helicobacter. 2020 Oct 18:e12766. doi: 10.1111/hel.12766.
    PubMed     Abstract available


  310. MIYATA E, Kudo T, Ikuse T, Tokita K, et al
    Eradication therapy for Helicobacter pylori infection based on the antimicrobial susceptibility test in children: A single-center study over 12 years.
    Helicobacter. 2020 Oct 18:e12764. doi: 10.1111/hel.12764.
    PubMed     Abstract available


  311. HOFREUTER D, Behrendt J, Franz A, Meyer J, et al
    Antimicrobial resistance of Helicobacter pylori in an eastern German region.
    Helicobacter. 2020 Oct 17:e12765. doi: 10.1111/hel.12765.
    PubMed     Abstract available


  312. SONG Z, Zhou L, Xue Y, Suo B, et al
    A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
    Helicobacter. 2020 Oct 11:e12762. doi: 10.1111/hel.12762.
    PubMed     Abstract available


  313. WANG B, Yu M, Zhang R, Chen S, et al
    A meta-analysis of the association between Helicobacter pylori infection and risk of atherosclerotic cardiovascular disease.
    Helicobacter. 2020 Oct 7:e12761. doi: 10.1111/hel.12761.
    PubMed     Abstract available


  314. ALVAREZ CS, Florio AA, Butt J, Rivera-Andrade A, et al
    Associations between Helicobacter pylori with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala.
    Helicobacter. 2020 Oct 2:e12756. doi: 10.1111/hel.12756.
    PubMed     Abstract available


  315. HUANG JW, Xie C, Niu Z, He LJ, et al
    The relation between Helicobacter pylori immunoglobulin G seropositivity and leukocyte telomere length in US adults from NHANES 1999-2000.
    Helicobacter. 2020 Oct 1:e12760. doi: 10.1111/hel.12760.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Peptic Ulcer is free of charge.